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ABSTRACT 
The high proportion of ductal carcinoma in situ (DCIS) presented in mammographic screening 
and the relatively low risk of progression to invasive disease have raised questions related to 
overtreatment. Following a review of current DCIS management protocols a more conservative 
approach has been suggested. Clinical trials have been introduced to evaluate the option of 
avoiding surgical intervention in a proportion of patients with DCIS defined as “low-risk” using 
certain clinicopathological criteria. These trials can potentially provide evidence-based models of 
active surveillance (with or without endocrine therapy) as a future management approach. 
Despite the undisputable fact of our need to address the obvious overtreatment of screen-detected 
DCIS, some important questions need to be considered regarding these trials including the 
eligibility criteria and definition of risk, the proportion of patient eligible for inclusion, and the 
length of time required for proper analysis of the trials’ outcome in view of the long-term natural 
history of DCIS progression particularly the low-risk group. These factors can potentially affect 
the practicality and future impact of such trials. This review provides critical analysis of current 
DCIS management trials and highlights critical issues related to their practicality and the 
expected outcome.  
INTRODUCTION 
Ductal carcinoma in situ (DCIS) refers to proliferation of malignant epithelial cells within the 
ducto-lobular system of the breast surrounded by a layer of myoepithelial cells and intact 
basement membrane [1]. The incidence of DCIS has significantly increased from less than 5% of 
breast cancer (BC) up to 20% of screen detected cancers following the introduction of 
mammographic screening [2, 3]. DCIS per se does not result in cancer-related mortality, 
however it is widely accepted that a significant proportion of DCIS lesions will progress to 
invasive cancer which is a potentially fatal disease. Despite limitation of the numbers and study 
cohort bias, available data indicates that between 14-53% of DCIS will progress to invasive 
carcinoma if left untreated within period of 10years or more [4, 5]. Despite this, almost all DCIS 
diagnosed in routine practice are treated by ablative surgery, with or without radiotherapy, due to 
lack of accurate prediction of its potential progression to an invasive lesion. The latter is the 
result of a combination of factors including: i) the complexity of the progression process with 
multiple molecular and biological variables, in addition to, interplay between malignant cells and 
surrounding microenvironment, ii) in vitro models are not optimal for assessment of DCIS 
progression and, iii) almost all DCIS are treated surgically and therefore recurrence can be as a 
result of a new primary, underestimation of the extent of the original DCIS lesion or progression 
of residual initially undetected DCIS foci. 
Recently, the value of population-based mammographic screening has been questioned in view 
of the balance between harm and benefits [6]. One important question raised is the over-
treatment of screen detected lesions; some of which are unlikely to kill the patients during their 
expected lifetime, which are mainly DCIS lesions, especially in the non-high risk groups[7, 8]. 
This view was supported by the high prevalence of DCIS (7–39%) found in autopsy studies of 
patients who died of causes other than BC and at age-group similar to that of population-based 
screening [9]providing evidence that a proportion of DCIS go undetected and does not cause 
significant symptoms or mortality. Other authors have questioned the legality of treating all 
DCIS patients with current standard methods to avoid an approximately 1% annual risk of 
progression to invasive disease [10]. Only half of DCIS recurrences, which are currently 
estimated at approximately 10-15% of all treated cases, are invasive [11, 12]. A large proportion 
of patients with DCIS will never develop invasive disease or die of BC even if left untreated. 
Moreover, the significant improvement in cancer molecular prognostic stratification in recent 
years has increased the possibility of utilising a personalised therapy approach[13, 14]; avoiding 
over-treatment and hence, preserving the quality of life and saving health service costs without 
compromising the outcomes presently achieved and limiting aggressive interventions to the high 
risk groups.    
The current standard treatment of all DCIS lesions is complete surgical excision with or without 
postoperative radiotherapy [15, 16]. Although breast conserving surgery (BCS) is widely used, 
there remains a high rate of surgical re-excisions or conversion to mastectomy and a proportion 
of patients are treated with mastectomy from the start. To reduce surgical intervention in screen-
detected DCIS, it has been suggested that patients with DCIS unlikely to progress to invasive 
disease can be subjected to active surveillance only [11, 17-20]. Subsequently multiple clinical 
trials (Table 1) aimed at assessing the safety of active surveillance as an alternative to surgical 
intervention in the so called “low-risk” DCIS group have been introduced including i) the LOw-
RISk DCIS (LORIS) trial, ii) the LOw Risk Dcis (LORD)trial, iii) Comparison of Operative to 
Monitoring and Endocrine Therapy (COMET) trial, and lastly the proposed trial; Low And 
intermediate RIsK ductal carcinoma IN situ study (LARRIKIN) trial. Although these trials are a 
way forward and the drive behind them is understandable, certain important questions should be 
considered to better comment on the practicality and expected outcome of these trials. These 
questions include: 1) have the inclusion criteria in these trials defined the low-risk group of 
DCIS patients precisely? 2) What is the percentage of DCIS patients who meet these criteria and 
to what extent will this approach be practical and rational? and, 3) What is the expected outcome 
that can be used as a measure of success in view of the long-term natural history of DCIS 
progression particularly in the low-risk group?  This review addresses these trials and highlights 
the definition of low-risk, their practical significance and expected outcome. 
DCIS and risk of progression 
Accurate risk stratification and precise definition of risk in DCIS remains a challenge not only 
because of the complexity and multifactorial nature of the disease but also due to the lack of 
definition of risk when BC mortality is considered as the outcome measure in the setting of 
mammographic screening. DCIS regardless of its grade, extent or even its recurrence as an in 
situ disease does not have potential to cause BC mortality. Even lesions which recur as/or 
progress to invasive disease do not have equal risk of mortality. Some invasive cancers develop 
after long interval time, and are indolent; therefore are unlikely to cause mortality in a population 
subjected to regular screening tests. Taken together, when defining risk in DCIS, the expected 
outcome should be considered in the development of a stratification system and in guiding 
management decisions.  
Although there is an increasing trend to define the risk using molecular profiling which can add 
value to current risk stratification or may be used solely in the future, these remain to be refined 
and validated [14, 21].The current risk stratification systems still rely on the more established 
clinicopathological parameters (Table 2). However, no single factor is sufficient on its own to 
define DCIS risk and a combination of multiple factors is used to stratify patients akin to 
invasive disease stratification. For instance patients aged more than 45 years old, with a small 
size DCIS (less than 15mm) that lacks comedo necrosis can be considered low-risk whereas 
patients with high grade lesions are considered high risk [22-24]. In addition, despite the fact that 
high grade DCIS is considered high-risk, only about half of them will recur or progress to 
invasive disease if left untreated; although there have been very few studies[4, 5]. 
Critical view to the current management trials 
To identify patients eligible for recruitment in the DCIS active surveillance clinical trials, the 
established clinicopathological risk factors have been utilised, despite the known limitations, as 
the only available parameters. Nuclear grade has been used as the main criterion for definition of 
low-risk DCIS in all trials. However; low grade DCIS comprises approximately 20% of cases [9, 
10]and this percent is much reduced when other inclusion criteria are considered; limiting the 
applicability of these trials to routine practice. In addition, cytonuclear grading of DCIS, which is 
the most commonly used grading method, is known to be subjective and with low concordance 
rates even amongst expert pathologists [25-29]. Trials based on the current simple nuclear 
grading system will be influenced by its inherent subjectivity. This view is supported by the very 
low number of patients recruited in the LORIS trial where only 100 patients have been recruited 
in the trial over 2-year period which has been reduced to 55 patients following central 
histopathology review prior to randomisation [30]. Other complex grading systems comparable 
to invasive cancer grading have been promoted [31] but are less reproducible and agreed.  
However, there remains scope for an improved and reproducible DCIS morphological grading 
system perhaps including cytonuclear grade combined with simple biomarkers such as Estrogen 
Receptor (ER), HER2 and growth pattern.  
Additionally, despite the strict inclusion criteria used to define low-risk DCIS in these trials, they 
cannot exclude the possibility of progression to invasive disease. Approximately 30% of low 
grade DCIS will progress to invasive disease within a period of 20 years if left untreated [32-34]. 
If we assume that the 30% chance of progression of low grade DCIS will be markedly reduced 
by the other selection criteria of the trials such as absence of necrosis (Table 1), these findings 
should alert us to intervals of interpretation of the trials’ results. Publication of the results of the 
trials which typically takes place after 3-5 years of follow-up, with a maximum of 10 years, is 
likely to underestimate the risk of progression and can produce confusion or misinterpretation of 
the findings in view of such long interval time to progression. Invasive recurrence, in context of 
low grade DCIS, usually develops after along lag period of between 10-40 years[4, 5, 35, 36]. 
This creates another critical point for the practice of ongoing trials in terms of prolonged follow 
up periods for early detection of such progression and adds more economic and psychological 
burden. In addition, DCIS lesions whatever the grade are non-fatal disease, and not all high grade 
DCIS will, inevitably, progress to invasive disease. So, end points of these studies should be 
revised as regard progression of low grade DCIS into a higher grade DCIS lesion and surgical 
intervention should be applied only to lesions progress to invasive carcinoma with only close 
follow up could be applied for such upgraded DCIS cases. This will add to understanding the 
natural history of the disease and increase the number of cases remained in the study follow up 
periods which add to their practicality.   
In contrast to a retrospective study from two UK centres investigated the adequacy of eligibility 
criteria for LORIS trial that showed no upgrading to invasive carcinoma after surgical excision 
of the tumours [37],  another study showed that 20% of cases eligible for LORIS trial were 
upgraded to invasive carcinoma in the final pathology report and 21% of them were high grade 
[38]. Pilewskie, et.al. studied more than 2,500 DCIS from which 405 patients met the LORIS 
trial inclusion criteria and reported that 6% of these patients treated with BCS alone developed 
ipsilateral invasive recurrences within 10 years [39]. Other studies for treatment of low grade 
DCIS with excision alone without radiotherapy showed higher incidence of recurrence, including 
invasive recurrence, [40-42] even for those asymptomatic women detected by mammographic 
screening [43, 44].The Radiation Therapy Oncology Group 9804 (RTOG-9804) study reported 
the local recurrence rate after excision alone for low-risk DCIS patients, defined as patients with 
mammographic detected grade I or II lesions measured 2.5cm or less with free margins at least 
3mm. Despite, the local recurrence rate was lower in low risk group (0.4%) than the high risk 
patients (3.5%), it was significantly decreased after addition of radiotherapy following BCS, a 
finding that may also raise a doubt about the accuracy of the current definition of low risk 
patients in terms of outcome [45]. A model was developed to predict the possibility of upgrading 
DCIS lesions, diagnosed with large core biopsy, to invasive carcinoma did not find any 
association between grade and upgrading where 27% and 25% of grade I and grade II lesions 
were upgraded to invasive carcinoma after excision, respectively [46].  
Inclusion criteria of these studies neglected some important parameters which can predict the 
presence of invasive carcinoma in initially diagnosed DCIS using core biopsy. Some studies 
showed that lesion size is an important factor for prediction of invasion in those patients 
[46-49].Models designed for DCIS diagnosed with vacuum assessed biopsies (VACB) to predict 
possibility of presence of invasive disease [50, 51]showed that size of the lesion was the main 
factor in prediction of presence of invasive lesion. Supporting its prognostic value, DCIS size is 
one of main parameters in the Van Nuys Prognostic Index (VNPI) for prediction of recurrence 
[52]. Surprisingly, DCIS size was not considered in eligibility criteria for these trials except in 
the proposed LARRIKIN trial. Additionally, pattern of micro-calcification on mammography, 
even without mass formation, is important and may reflect aggressive disease which also may 
not be detected histologically in taken biopsy materials [53]. LORD and COMET trials clearly 
define that point in their eligibility criteria which is not taken into account in the other two trials.  
Lastly, phenotypic and genotypic heterogeneity of DCIS lesions also provides a great challenge 
in risk stratification and hence in decided management approach [54]. Current trials rely mainly 
on VACB which provide more tissue for examination than core biopsies. However, this may not 
fully represent the heterogeneity of DCIS. About 16% of low nuclear grade DCIS is mixed with 
either intermediate or high grade foci [54-56]. Reviewing 1,059 cases of pure DCIS lesions 
diagnosed between 1990-2013 in Nottingham revealed that 13% of cases were pure low nuclear 
grade while 5.5% and 1.5% of low grade lesion were mixed with intermediate or intermediate 
and high grades respectively (unpublished data).Therefore biopsies from multiple areas 
especially in large size DCIS may be warranted to ensure accurate representation.   
Despite the potential prognostic value of molecular classification of DCIS, the inclusion criteria 
of the current trials, apart from COMET study which includes the basic biomarkers; i.e. Estrogen 
Receptor (ER), Progesterone Receptor (PR) and HER2, do not include molecular biomarker 
profiles. Molecular studies of DCIS with the Oncotype DX assay, for instance, showed that a 
subset of intermediate grade DCIS has high score and hence potentially have a higher risk for 
recurrence and progression [14]. The Eastern Cooperative Oncology Group (ECOG) E5194 
study which performed to evaluate treatment of DCIS with excision alone has also shown that 
some of the low and intermediate grade DCIS had a high Oncotype DX score indicating that a 
subgroup of these morphologically low-risk DCIS have a potentially higher possibility of 
recurrence and progression [57, 58].The recent application of next generation sequencing (NGS) 
to investigate the molecular characterisation of DCIS is expected to improve our understanding 
the natural history of these lesions and may provide a more powerful tool for risk stratification of 
DCIS patients [59, 60].  Although we expect more refinement of the prognostic classification of 
DCIS in the future, the current available molecular data may have helped to complement 
morphological features to identify more patient eligible for the these trials and avoid inclusion of 
those who are likely to progress based on morphological features alone.  
Conclusions and recommendations: Although the current management approaches of 
DCIS, particularly the more common screen-detected lesions, can be considered overtreatment, 
at least in a proportion of cases, the precise criteria to identify low-risk patients are still not fully 
clear. Current trials for management low-risk DCIS by active surveillance are welcomed and is a 
promising approach to provide evidence-based data on such approaches as well as their role in 
understanding the natural history of DCIS lesions. Clarifying the limitations of such trials should 
be considered to increase the potential successful outcome. More precise definitions of low-risk 
patients including molecular profiling are needed not only to refine the classification of risk but 
also to increase the proportion of DCIS patients’ eligible for these trials. Lesion size should be 
considered in inclusion criteria and multiple biopsies from large size lesions are warranted to 
avoid downgrading of heterogeneous lesions. In addition, the long natural history of progression 
of low-risk DCIS to invasive disease should be considered in terms of duration of follow-up, 
active surveillance period, interpretation of initial results, defining the trials end points and the 
expected overall outcome. Accurate and reliable interpretation of trial findings should be 
addressed following publications of 10, 15 and even 20 years of follow-up. Recurrence as DCIS 
should not be considered as the final endpoint or a reason for surgical intervention but only 
recurrences as invasive disease should be used as an endpoint. Moreover, recurrent high grade 
DCIS has no mortality risk and will not inevitable progress to invasive carcinoma, so it should 
not be used a sign of inferiority or failure of intervention. Closer follow up for these patients may 
be an option. Finally, the current trials randomise between the extremes of potential management 
– surveillance only versus surgical ablative therapy with or without radiotherapy. Could there be 
potential for alternative non-invasive or minimally invasive approaches to ablation than invasive 
conventional surgery and could these prove to be the solution for management of low-risk breast 
neoplastic lesions both in-situ and invasive? 
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Table 1 Current trials comparing management of DCIS by active surveillance against 
surgical treatment  
Study Inclusion criteria Exclusion criteria P a t i e n t s recruitment
M a i n E n d 
points
Number 
o f 
patients 
required
The Low-risk 
D C I S T r i a l 
( L O R I S 
TRIAL) [17] 
(UK study) 
* Female, aged 46 years 
or more 
* Non high grade DCIS 
(un i - o r b i l a t e r a l ) 
d e t e c t e d t h r o u g h 
S c r e e n i n g 
m a m m o g r a p h y o r 
i n c i d e n t a l m i c r o -
c a l c i f i c a t i o n a n d 
c o n f i r m e d 
histologically through 
Vacuum Assisted Core 
Biopsy (VACB) or 
VA C B p l u s o p e n 
diagnost ic surgical 
biopsy (without clear 
margins) 
* Patients should be 
able to give informed 
consent and  fit to 
undergo surgery
* Previous or current 
invasive breast cancer or 
p rev ious ips i l a te ra l 
DCIS (i.e. recurrent 
DCIS)  
* Symptomatic patient 
with a mass lesion or 
blood stained nipple 
d i s c h a r g e w i t h o u t 
ev idence of benign 
lesion   
* Histologically detected 
unequivocal comedo 
necrosis 
* Patients at high risk for 
developing invasive 
breast cancer (as defined 
in NICE guidelines for 
familial breast cancer or 
due to previous exposure 
to radiotherapy) 
July 2014 Occurrence 
of ipsilateral 
i n v a s i v e 
breast cancer 
w i t h i n 
f o l l o w u p 
period of10 
years.  
932
Low-risk Dcis 
Trial (LORD) 
trial [11] 
(Europe Study) 
*Non pregnant, non-
breastfeeding Female, 
aged 45 years or more. 
* Asymptomatic lesions 
d e t e c t e d t h r o u g h 
s c r e e n i n g 
m a m m o g r a p h y a s 
calcification only lesion 
( o f a n y s i z e ) a n d 
c o n f i r m e d 
histologically through 
representative VACB as 
pure low grade DCIS 
w i t h a d e q u a t e 
consistency between 
p a t h o l o g i c a l a n d 
radiological findings 
i.e. no suspicion of 
intermediate or high 
grade DCIS or invasive 
breast cancer 
* Fit patients for the 
t r ia l and informed 
consent is necessary.  
* Symptomatic DCIS 
either with mass, nipple 
discharge or lesions with 
marked archi tecture 
d i s t o r t i o n o n 
mammography.  
* Bilateral DCIS or 
those associated with 
P a g e t ’s d i s e a s e o r 
lobular neoplasia    
* P r e v i o u s o r 
synchronous invasive 
breast carcinoma in the 
contralateral breast or 
previous history of DCIS 
in any side   
* Patients unfit for trial 
due to serious disease or 
have previous history for 
malignancy (apart from 
carcinoma in situ of the 
cervix or basal cell 
carcinoma of the skin). 
* Individual from a 
family with a known 
BRCA1/2 mutation
Not yet Occurrence 
of ipsilateral 
i n v a s i v e 
breast cancer 
o r h i g h e r 
grade DCIS 
(grade II or 
I I I ) wi th in 
f o l l o w u p 
period of 10 
years.  
1240
Comparison of 
Operative to 
Monitoring and 
Endocrine 
Therapy 
(COMET) Trial 
For Low-risk 
DCIS [61] 
(USA Study)
* Non-pregnant 
Female, aged 40 years 
or more  
* Pure unifocal or 
multifocal low or 
intermediate DCIS 
(uni- or bilateral) 
without comedo 
necrosis diagnosed 
histologically by needle 
core biopsy (from 2 
sites of lesions measure 
more than 4cm). 
* Lesions should be 
Estrogen Receptor (ER)
(+) and/or Progesterone 
Receptor (PR)(+) by 
Immunohistochemistry 
(IHC) (≥ 10% staining 
or Allred score ≥ 4) and 
negative for HER2/neu 
* No previous history 
of breast cancer in 
either breast 
* Fit patients for the 
trial and surgery 
confirmed with normal 
baseline blood tests and 
renal functions.   
* Informed constant 
* Previous or concurrent 
invasive breast cancer, or 
previous history of 
usages anti oestrogens 
* Symptomatic cases 
with mass formed 
lesions or bloody nipple 
discharge   
* Suspicious of invasive 
disease in 
mammography  
* Unfit patients with 
serious diseases  
Not yet Occurrence 
of ipsilateral 
i n v a s i v e 
breast cancer 
o r h i g h e r 
grade DCIS 
(grade II or 
I I I ) wi th in 
f o l l o w u p 
period of 5 
years.  
1189
Low And 
InteRmediate 
RIsK ductal 
carcinoma IN 
situ study 
(LARRIKIN) 
Trial [10]. 
Australian  
Study  
* Non pregnant, non-
lactating Female, aged 
55 years or more 
* Pure, asymptomatic 
screen detected uni- or 
bilateral, unifocal DCIS 
(low and intermediate 
grade) measures 2cm or 
less based on either a 
core biopsy and/or 
VACB or open 
diagnostic surgical 
biopsy.
* No previous or current 
diagnosis of invasive 
cancer, previous 
ipsilateral 
DCIS, Paget's disease or 
LCIS, 
*Patients with BRCA1/2 
mutation
N o t y e t 
( p r o p o s e d 
t r a i l ; 
f u n d i n g 
requirement 
submitted) 
Occurrence 
of ipsilateral 
i n v a s i v e 
breast cancer 
o r h i g h e r 
grade DCIS 
(grade II or 
I I I ) wi th in 
f o l l o w u p 
period of 5 
years.  
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Table 2 Pre-operative risk factors of DCIS recurrence and progression 
Factor Risk References  
Age The risk of DCIS invasive recurrence is 
2-3 folds in patients younger than 50 
years 
[62-64]
Symptomatic patient Symptomatic DCIS has higher risk for 
invasive recurrence than screen-detected 
patients
[65-67]
Family history Patients with positive family history of 
breast cancer are more liable for invasive 
recurrence after treatment of DCIS
[21, 68, 69]
DCIS size and focality Large size (more than 4cm) and/or 
multifocal DCIS lesions have higher risk 
for recurrence than small sized 
[67, 70, 71]
Tumour grade High grade DCIS are more likely to 
recur; mainly invasive; than low grade 
one 
[21, 67, 72, 73]
Comedo necrosis Lesions associated with comedo necrosis 
have higher incidence of recurrence 
especially invasive recurrence 
[67, 74]
Molecular subtypes Lesions with HER2 positivity are at high 
risk for tumour recurrence 
[21]
